<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02429934</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-330 SLE Arthritis</org_study_id>
    <nct_id>NCT02429934</nct_id>
  </id_info>
  <brief_title>Abatacept for SLE Arthritis (IM101-330)</brief_title>
  <official_title>Efficacy of Abatacept in Inflammatory Polyarthritis of Systemic Lupus Erythematosus (SLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research trial is for patients who have been diagnosed with systemic lupus erythematosus&#xD;
      (SLE) with swollen, tender joints (which is called inflammatory polyarthritis) because of the&#xD;
      SLE.&#xD;
&#xD;
      The purpose of this clinical research study is to evaluate the safety and effectiveness of&#xD;
      treatment with abatacept (Abatacept) 125mg injected subcutaneously (under the skin) weekly&#xD;
      for 16 weeks versus placebo injections(a substance with no active ingredients and therefore&#xD;
      may have no treatment benefit) in subjects with SLE and inflammatory polyarthritis. The&#xD;
      effectiveness will be assessed primarily by the number of swollen, tender joints (called a&#xD;
      joint count) at each of study visits.&#xD;
&#xD;
      Study Medication Abatacept is approved in the U.S. for treating rheumatoid arthritis by&#xD;
      prescription and has not been approved by the U.S. Food and Drug Administration for treating&#xD;
      SLE yet.&#xD;
&#xD;
      In this study, subjects will receive treatment with either abatacept or placebo once a week&#xD;
      for 16 weeks (a total of 16 injections).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Response rate in placebo group for primary outcome was 100% on interim analysis.&#xD;
  </why_stopped>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">September 1, 2019</completion_date>
  <primary_completion_date type="Actual">September 1, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With at Least a 20% Improvement From Baseline in Tender and Swollen 28 Joint Count</measure>
    <time_frame>Baseline, 8 Weeks, 16 Weeks</time_frame>
    <description>Assessed by physical exam. Total number of joints that are both swollen and tender were assessed in each participant by a physician at each study visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in SLEDAI 2K</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Systemic Lupus Erythematosus Disease Activity Index (Modified in the year 2000) - The SLEDAI-2K is a modified version of a composite score based on the presence or absence of clinical signs, clinical symptoms, and immunologic laboratory results taken within 10 days of the evaluations. Each of the descriptors has a weighted score and the total score of SLEDAI-2K is the sum of all 24 descriptor scores. The total SLEDAI-2K score falls between 0 and 105, with higher scores representing higher disease activity. Decrease of 3 points in SLEDAI 2K is considered to be a clinically significant improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the PGA Score</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Physician's Global Assessment (PGA) is a physician rating of patient's disease activity, with a range 0-3. A change of 0.8 points on a 3 point scale or less is considered as stable. Lower score means better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Disease Activity Index (CDAI) Index Score</measure>
    <time_frame>16 weeks</time_frame>
    <description>CDAI is a simplified index for assessing disease activity comprising swollen joint counts (SJC), tender/painful joint counts (TJC), participant's global assessment of disease activity (PtGA) and physician's global assessment of disease activity (PGA). CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment), PtGA and PGA (assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0-76. CDAI less than equal to (&lt;=) 2.8 indicates disease remission, greater than (&gt;) 2.8 to 10 = low disease activity, greater than (&gt;) 10 to 22 = moderate disease activity, and &gt;22 = high disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Synovitis, Tenosynovitis and Erosions Scores (GSUS and PDUS)</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Using ultrasound analysis, (Gray scale ultrasound) represents synovitis/tenosynovitis and identifies erosions. PDUS (power Doppler ultrasound) measures intensity of soft tissue inflammation by blood flow. 30 joints were evaluated using a 0 to 3 point scale for each joint and the sum of these represents PDUS. The Power Doppler Synovitis Score (PDUS) ranges from 0 to 90. Scores of 0 indicate the least amount of inflammation. A higher value of the total score for PDUS represents more severe disease level. 30 joints were evaluated using a 0 to 3 point scale for each joint and the sum of these represents GSUS. The grey scale synovial hypertrophy score (GSUS) ranges from 0 to 90. Scores of 0 indicate the least amount of inflammation of the joint. A higher value of the total score for GSUS represents more severe disease level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AEs and SAEs</measure>
    <time_frame>16 weeks</time_frame>
    <description>Total number of AEs and total number of SAEs as well as those AEs/SAEs which may be related to the study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Tender and Swollen Joints</measure>
    <time_frame>baseline, 4, 8, 12 and 16 weeks</time_frame>
    <description>Total number of joints that are both swollen and tender were assessed in each participant by a physician at each study visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Total Sum of Tender and Swollen Joints</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Total number of joints that are both swollen and tender were assessed in each participant by a physician at each study visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Tapered Prednisone to &lt;10mg/Day</measure>
    <time_frame>16 weeks</time_frame>
    <description>This analysis is for the subset of patients who start the study taking 10 to 20mg of prednisone per day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Prednisone Dose (mg/Day)</measure>
    <time_frame>Baseline, 8 and 16 weeks</time_frame>
    <description>prednisone dose (mg/day) is recorded at baseline, 8 and 16 weeks for each subject being assessed at that study visit. Then a mean for all the subjects in each group at each time point was calculated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Systemic Lupus Erythematosus Arthritis</condition>
  <arm_group>
    <arm_group_label>Abatacept also known as Orencia also known as CTLA4Ig</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>32 SLE patients to be treated with subcutaneous abatacept 125mg sq once a week for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>32 SLE patients to be treated with subcutaneous placebo once a week for 16 weeks. Injection will be vehicle injected subcutaneously once a week for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>abatacept also known as Orencia also known as CTLA4-Ig</intervention_name>
    <description>125mg injected subcutaneously weekly for 16 weeks</description>
    <arm_group_label>Abatacept also known as Orencia also known as CTLA4Ig</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meet at least 4 of the 11 American College of Rheumatology (ACR) 1997 criteria for&#xD;
             classification of SLE (see Appendix 1).OR meet the recent classification recommended&#xD;
             by SLICC (Appendix 2) 6&#xD;
&#xD;
          2. ≥3 swollen and tender joints on 2 examinations at least 2 weeks apart and no more than&#xD;
             8 weeks apart.&#xD;
&#xD;
          3. SLEDAI2K score ≥4 indicating active disease.&#xD;
&#xD;
          4. Documented positive ANA (≥1:80) and/or anti-dsDNA during course of SLE.&#xD;
&#xD;
          5. Men and women, at least 18 years of age. Women of childbearing potential must use&#xD;
             adequate method(s) of contraception to avoid pregnancy throughout the study and for up&#xD;
             to 2 months after last study drug dose. They must have a negative serum or urine&#xD;
             pregnancy test prior to the start of study medication.&#xD;
&#xD;
          6. Background therapies allowed: antimalarials (dose constant for ≥ one month before&#xD;
             study entry and during 16 weeks of trial), methotrexate (same criteria as for&#xD;
             antimalarials), azathioprine (same criteria), mycophenolate (same criteria),&#xD;
             leflunomide (same criteria).&#xD;
&#xD;
        During the screening period and for up to 6 weeks after randomization, a daily prednisone&#xD;
        (or equivalent) regimen of up to 20 mg daily may be initiated to treat the moderate to&#xD;
        severe disease activity present at screening. The initial steroid regimen is not required&#xD;
        if investigators or patients believe that the risks would outweigh the potential benefits.&#xD;
        Patients who do not take any glucocorticoids during the study will be included in the&#xD;
        treatment groups and analysis.&#xD;
&#xD;
        *Steroids should be tapered to a target dose of no more than 10 mg/day of prednisone (or&#xD;
        equivalent) by the end of Week 8 (Day 56). The steroid regimen should be tapered as quickly&#xD;
        as safely possible. Prednisone dose requirements higher than 10 mg daily at the 8 week&#xD;
        visit will cause the patient to be ruled a non-responder for the abatacept treatment arm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with active infection requiring oral or IV antibiotics within one month of&#xD;
             first dose of study medication.&#xD;
&#xD;
          2. Subjects with BILAG A in any system outside the musculoskeletal system.&#xD;
&#xD;
          3. Subjects with positive quantiferon Gold test in the absence of treatment for&#xD;
             tuberculosis.&#xD;
&#xD;
          4. Subjects with positive tests for active infection with hepatitis B or C during the&#xD;
             past 6 months. Any confirmed positive test for HIV at any time prior to entry into&#xD;
             this study.&#xD;
&#xD;
          5. Subjects with active glomerulonephritis (&gt;3 g protein/24h and/or active urine&#xD;
             sediment).&#xD;
&#xD;
          6. Subjects with active CNS disease.&#xD;
&#xD;
          7. Subjects with any other serious disease that would require immunosuppressive or&#xD;
             parenteral anti-microbial therapy outside the study protocol.&#xD;
&#xD;
          8. Inability to self-administer subcutaneous injections, to comply with instructions, or&#xD;
             to keep appointments for study visits.&#xD;
&#xD;
          9. Treatment with rituximab within the past 6 months (B cells must be detectable in&#xD;
             peripheral blood at onset of treatment with study biologic), belimumab within the past&#xD;
             5 months, cyclophosphamide within the past 3 months.&#xD;
&#xD;
         10. Treatment with any other immunomodulatory biologic or cyclophosphamide during&#xD;
             treatment with abatacept is not allowed.&#xD;
&#xD;
         11. Patients requiring &gt;20 mg of prednisone daily.&#xD;
&#xD;
         12. Women who are pregnant or breast feeding.&#xD;
&#xD;
         13. Women of child bearing potential unwilling or unable to use an acceptable method to&#xD;
             avoid pregnancy for the entire study period and for up to 2 months after last study&#xD;
             drug.&#xD;
&#xD;
         14. Subjects with a history of cancer within the last five years (other than non-melanoma&#xD;
             skin cell cancers cured by local resection).&#xD;
&#xD;
         15. Any laboratory test results that, in the opinion of the Investigator, might place the&#xD;
             subject at unacceptable risk for participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bevra Hahn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA David Geffen School of Medicine, Division of Rheumatology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 24, 2015</study_first_submitted>
  <study_first_submitted_qc>April 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <results_first_submitted>September 15, 2020</results_first_submitted>
  <results_first_submitted_qc>May 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 13, 2021</results_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic Lupus Erythematosus (SLE)</keyword>
  <keyword>Abatacept (Orencia)</keyword>
  <keyword>Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT02429934/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Abatacept</title>
          <description>abatacept: 125mg injected subcutaneously weekly for 16 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo subcutaneous injection weekly for 16 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Abatacept</title>
          <description>abatacept: 125mg injected subcutaneously weekly for 16 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo subcutaneous injection weekly for 16 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.6" spread="9.0"/>
                    <measurement group_id="B2" value="40.8" spread="15.3"/>
                    <measurement group_id="B3" value="42.2" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>education</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>high school</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 year college</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 year college</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>trade school</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>master's degree</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>professional</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>insurance</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>PPO</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>HMO</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Medicare</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Medicaid</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>smoking history</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>never smoked</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>past smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>current smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With at Least a 20% Improvement From Baseline in Tender and Swollen 28 Joint Count</title>
        <description>Assessed by physical exam. Total number of joints that are both swollen and tender were assessed in each participant by a physician at each study visit.</description>
        <time_frame>Baseline, 8 Weeks, 16 Weeks</time_frame>
        <population>subjects that completed the 8 and 16 week study visits</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>abatacept: 125mg injected subcutaneously weekly for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo subcutaneous injection weekly for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least a 20% Improvement From Baseline in Tender and Swollen 28 Joint Count</title>
          <description>Assessed by physical exam. Total number of joints that are both swollen and tender were assessed in each participant by a physician at each study visit.</description>
          <population>subjects that completed the 8 and 16 week study visits</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SLEDAI 2K</title>
        <description>Systemic Lupus Erythematosus Disease Activity Index (Modified in the year 2000) - The SLEDAI-2K is a modified version of a composite score based on the presence or absence of clinical signs, clinical symptoms, and immunologic laboratory results taken within 10 days of the evaluations. Each of the descriptors has a weighted score and the total score of SLEDAI-2K is the sum of all 24 descriptor scores. The total SLEDAI-2K score falls between 0 and 105, with higher scores representing higher disease activity. Decrease of 3 points in SLEDAI 2K is considered to be a clinically significant improvement.</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <population>completers at 16 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>abatacept: 125mg injected subcutaneously weekly for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo subcutaneous injections weekly for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SLEDAI 2K</title>
          <description>Systemic Lupus Erythematosus Disease Activity Index (Modified in the year 2000) - The SLEDAI-2K is a modified version of a composite score based on the presence or absence of clinical signs, clinical symptoms, and immunologic laboratory results taken within 10 days of the evaluations. Each of the descriptors has a weighted score and the total score of SLEDAI-2K is the sum of all 24 descriptor scores. The total SLEDAI-2K score falls between 0 and 105, with higher scores representing higher disease activity. Decrease of 3 points in SLEDAI 2K is considered to be a clinically significant improvement.</description>
          <population>completers at 16 weeks</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4545" spread="3.2669"/>
                    <measurement group_id="O2" value="-3.4000" spread="2.8363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the PGA Score</title>
        <description>Physician's Global Assessment (PGA) is a physician rating of patient's disease activity, with a range 0-3. A change of 0.8 points on a 3 point scale or less is considered as stable. Lower score means better outcome</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <population>SLE subjects completing 16 weeks of treatment or placebo and attending the 16-week physician assessment visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>abatacept: 125mg injected subcutaneously weekly for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo subcutaneous injection weekly for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the PGA Score</title>
          <description>Physician's Global Assessment (PGA) is a physician rating of patient's disease activity, with a range 0-3. A change of 0.8 points on a 3 point scale or less is considered as stable. Lower score means better outcome</description>
          <population>SLE subjects completing 16 weeks of treatment or placebo and attending the 16-week physician assessment visit.</population>
          <units>points on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3650" spread="3.7029"/>
                    <measurement group_id="O2" value="-0.3350" spread="2.2289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Disease Activity Index (CDAI) Index Score</title>
        <description>CDAI is a simplified index for assessing disease activity comprising swollen joint counts (SJC), tender/painful joint counts (TJC), participant's global assessment of disease activity (PtGA) and physician's global assessment of disease activity (PGA). CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment), PtGA and PGA (assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0-76. CDAI less than equal to (&lt;=) 2.8 indicates disease remission, greater than (&gt;) 2.8 to 10 = low disease activity, greater than (&gt;) 10 to 22 = moderate disease activity, and &gt;22 = high disease activity.</description>
        <time_frame>16 weeks</time_frame>
        <population>sle subjects that completed 16 week assessment visit</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>abatacept: 125mg injected subcutaneously weekly for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo subcutaneous injection weekly for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Disease Activity Index (CDAI) Index Score</title>
          <description>CDAI is a simplified index for assessing disease activity comprising swollen joint counts (SJC), tender/painful joint counts (TJC), participant's global assessment of disease activity (PtGA) and physician's global assessment of disease activity (PGA). CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment), PtGA and PGA (assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0-76. CDAI less than equal to (&lt;=) 2.8 indicates disease remission, greater than (&gt;) 2.8 to 10 = low disease activity, greater than (&gt;) 10 to 22 = moderate disease activity, and &gt;22 = high disease activity.</description>
          <population>sle subjects that completed 16 week assessment visit</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7850" spread="12.0459"/>
                    <measurement group_id="O2" value="14.5700" spread="7.9701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Synovitis, Tenosynovitis and Erosions Scores (GSUS and PDUS)</title>
        <description>Using ultrasound analysis, (Gray scale ultrasound) represents synovitis/tenosynovitis and identifies erosions. PDUS (power Doppler ultrasound) measures intensity of soft tissue inflammation by blood flow. 30 joints were evaluated using a 0 to 3 point scale for each joint and the sum of these represents PDUS. The Power Doppler Synovitis Score (PDUS) ranges from 0 to 90. Scores of 0 indicate the least amount of inflammation. A higher value of the total score for PDUS represents more severe disease level. 30 joints were evaluated using a 0 to 3 point scale for each joint and the sum of these represents GSUS. The grey scale synovial hypertrophy score (GSUS) ranges from 0 to 90. Scores of 0 indicate the least amount of inflammation of the joint. A higher value of the total score for GSUS represents more severe disease level.</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <population>completers of 16 weeks of treatment/placebo at one study center (UCLA)</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>abatacept: 125mg injected subcutaneously weekly for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo subcutaneous injection weekly for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Synovitis, Tenosynovitis and Erosions Scores (GSUS and PDUS)</title>
          <description>Using ultrasound analysis, (Gray scale ultrasound) represents synovitis/tenosynovitis and identifies erosions. PDUS (power Doppler ultrasound) measures intensity of soft tissue inflammation by blood flow. 30 joints were evaluated using a 0 to 3 point scale for each joint and the sum of these represents PDUS. The Power Doppler Synovitis Score (PDUS) ranges from 0 to 90. Scores of 0 indicate the least amount of inflammation. A higher value of the total score for PDUS represents more severe disease level. 30 joints were evaluated using a 0 to 3 point scale for each joint and the sum of these represents GSUS. The grey scale synovial hypertrophy score (GSUS) ranges from 0 to 90. Scores of 0 indicate the least amount of inflammation of the joint. A higher value of the total score for GSUS represents more severe disease level.</description>
          <population>completers of 16 weeks of treatment/placebo at one study center (UCLA)</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline GSUS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.50" spread="7.05"/>
                    <measurement group_id="O2" value="16.00" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 week GSUS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.75" spread="2.22"/>
                    <measurement group_id="O2" value="17.75" spread="5.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline PDUS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.25" spread="5.12"/>
                    <measurement group_id="O2" value="1.50" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 week PDUS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="1.83"/>
                    <measurement group_id="O2" value="2.25" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of AEs and SAEs</title>
        <description>Total number of AEs and total number of SAEs as well as those AEs/SAEs which may be related to the study drug</description>
        <time_frame>16 weeks</time_frame>
        <population>All subjects dosed with either abatacept or placebo at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>abatacept: 125mg injected subcutaneously weekly for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo subcutaneous injection weekly for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of AEs and SAEs</title>
          <description>Total number of AEs and total number of SAEs as well as those AEs/SAEs which may be related to the study drug</description>
          <population>All subjects dosed with either abatacept or placebo at least once.</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs grade II or less</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs not related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs possibly related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs probably related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs grade III or higher</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Tender and Swollen Joints</title>
        <description>Total number of joints that are both swollen and tender were assessed in each participant by a physician at each study visit</description>
        <time_frame>baseline, 4, 8, 12 and 16 weeks</time_frame>
        <population>Each timepoint reports the number of participants who attended each visit for physician assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>abatacept: 125mg injected subcutaneously weekly for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo subcutaneous injection weekly for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Tender and Swollen Joints</title>
          <description>Total number of joints that are both swollen and tender were assessed in each participant by a physician at each study visit</description>
          <population>Each timepoint reports the number of participants who attended each visit for physician assessment</population>
          <units>joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.73" spread="4.53"/>
                    <measurement group_id="O2" value="5.00" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.80" spread="2.65"/>
                    <measurement group_id="O2" value="1.54" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="2.13"/>
                    <measurement group_id="O2" value="0.45" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="2.19"/>
                    <measurement group_id="O2" value="1.00" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="2.27"/>
                    <measurement group_id="O2" value="0.50" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Total Sum of Tender and Swollen Joints</title>
        <description>Total number of joints that are both swollen and tender were assessed in each participant by a physician at each study visit</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>abatacept: 125mg injected subcutaneously weekly for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo subcutaneous injection weekly for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Total Sum of Tender and Swollen Joints</title>
          <description>Total number of joints that are both swollen and tender were assessed in each participant by a physician at each study visit</description>
          <units>Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1818" spread="4.2619"/>
                    <measurement group_id="O2" value="-4.2000" spread="1.3116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Tapered Prednisone to &lt;10mg/Day</title>
        <description>This analysis is for the subset of patients who start the study taking 10 to 20mg of prednisone per day.</description>
        <time_frame>16 weeks</time_frame>
        <population>This analysis is for the subset of patients who start the study taking 10 to 20mg of prednisone per day. Among all the subjects entered, 6 in each group were taking 10 mg of prednisone daily or higher at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>abatacept: 125mg injected subcutaneously weekly for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo injected subcutaneously weekly for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Tapered Prednisone to &lt;10mg/Day</title>
          <description>This analysis is for the subset of patients who start the study taking 10 to 20mg of prednisone per day.</description>
          <population>This analysis is for the subset of patients who start the study taking 10 to 20mg of prednisone per day. Among all the subjects entered, 6 in each group were taking 10 mg of prednisone daily or higher at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Prednisone Dose (mg/Day)</title>
        <description>prednisone dose (mg/day) is recorded at baseline, 8 and 16 weeks for each subject being assessed at that study visit. Then a mean for all the subjects in each group at each time point was calculated.</description>
        <time_frame>Baseline, 8 and 16 weeks</time_frame>
        <population>Results are reported for the number of participants who completed the study visit/assessment at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>abatacept: 125mg injected subcutaneously weekly for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo subcutaneous injection weekly for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Prednisone Dose (mg/Day)</title>
          <description>prednisone dose (mg/day) is recorded at baseline, 8 and 16 weeks for each subject being assessed at that study visit. Then a mean for all the subjects in each group at each time point was calculated.</description>
          <population>Results are reported for the number of participants who completed the study visit/assessment at each time point</population>
          <units>mg per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.73" spread="7.73"/>
                    <measurement group_id="O2" value="4.77" spread="6.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.46" spread="7.98"/>
                    <measurement group_id="O2" value="5.64" spread="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.45" spread="10.04"/>
                    <measurement group_id="O2" value="5.70" spread="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for 20 weeks after initial dose (visit 1)</time_frame>
      <desc>We used clinicaltrials.gov definitions</desc>
      <group_list>
        <group group_id="E1">
          <title>Abatacept</title>
          <description>abatacept: 125mg injected subcutaneously weekly for 16 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo subcutaneous injection weekly for 16 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>flare of lupus nephritis</sub_title>
                <description>Patient developed increased proteinuria, was removed from clinical trial and treated with increased immunosuppression and problem resolved, Judged not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin reaction at injection site</sub_title>
                <description>soreness and tenderness around point of subcutaneous injection for 1-2 days post injection</description>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bevra Hahn</name_or_title>
      <organization>University of California at Los Angeles</organization>
      <phone>8184869745 ext 8184869745</phone>
      <email>bhahn@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

